IL17A

(redirected from interleukin-17A)

IL17A

A gene on chromosome 6p12 that encodes interleukin-17A, a proinflammatory cytokine produced by activated T cells which regulates NF-kappaB and mitogen-activated protein kinases. It upregulates IL6 and cyclooxygenase-2 and increases nitric oxide production.

Molecular pathology
IL17A is overexpressed in rheumatoid arthritis, psoriasis and multiple sclerosis.
References in periodicals archive ?
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
The product is claimed to be the first and only fully-human biologic, which directly restricts interleukin-17A (IL-17A), a cornerstone cytokine engaged in the inflammation and development of PsA, psoriasis, and ankylosing spondylitis.
Novartis announced that the China Health Authority NMPA approved Cosentyx, the first-in-class interleukin-17A inhibitor for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
The rationale for investigating secukinumab (Cosentyx), a biologic that blocks the interleukin-17A receptor and is approved for treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis, lies in the observation that HS lesions exhibit an increased ratio of Th17- to T-regulatory cells, compared with normal skin.
Cosentyx is the first and only fully-human treatment that specifically inhibits interleukin-17A (IL-17A), in psoriatic arthritis (PsA).
According to the researches, targeting this molecule, interleukin-17a, offered another potential avenue for preventing autism in people.
The company said Cosentyx is a fully human monoclonal antibody (mAB) that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.
This agent may work through inhibiting proinflammatory mediators including interleukin-6 and interleukin-17A. The topical 1% cream is being studied for both AD and psoriasis.
Protective immunity against recurrent Staphylococcus aureus skin infection requires antibody and interleukin-17A. Infect Immun 2014; 82: 2125-2134, doi: 10.1128/IAI.01491-14.
Volz, "Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab," Acta Dermato-Venereologica, vol.
Peck, "Pathogenic effect of interleukin-17A in induction of Sjogren's syndrome-like disease using adenovirus-mediated gene transfer," Arthritis Research & Therapy, vol.
Interleukin-17A (IL-17A) participates in the pathogenesis of several immune and inflammatory diseases and upregulates expression of numerous inflammation-related genes [42].